Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin

Purpose Sodium-glucose cotransporter 2 inhibitors increase glucagon secretion by pancreatic alpha cells and the susceptibility to ketoacidosis. On the other hand, growth hormone (GH) stimulates peripheral lipolysis and provides free fatty acids (FFA) for ketogenesis; however, it remains unresolved whether GH directly impacts hepatic ketogenesis. We aimed to investigate the role of physiologic GH levels in promoting ketogenesis in prediabetic or type 2 diabetic patients under empagliflozin treatment. Methods Sixteen patients (11 women, 5 men) with prediabetes or type 2 diabetes mellitus, aged 55.6 +/- 4.7 years and with a mean BMI of 30.7 +/- 4.8 kg/m(2) and HbA1c 7.1 +/- 1.6% (means +/- SD), participated in this study. All of them were submitted to three mixed-meal tests: they received placebo at -60 min (test 1), and empagliflozin 25 mg (test 2, 21st day) and empagliflozin 25 mg plus pegvisomant 30 mg were administered subcutaneously 36 h before (test 3, 28th day). After test 1, all patients were instructed to take empagliflozin 25 mg daily. Results The empagliflozin treatment decreased the plasma concentrations of glucose by 14% (P < 0.01), FFA by 23% (P < 0.01), and the insulin/glucagon ratio by 26% (P < 0.01), and it increased beta-hydroxybutyrate by 44% (P < 0.05). The GH receptor block by pegvisomant restored the plasma beta-hydroxybutyrate to baseline levels. Conclusions We conclude that GH has a direct effect on promoting the ketogenesis environment in patients treated with empagliflozin.

Automated summary

The study investigated the role of growth hormone in promoting ketogenesis in patients treated with empagliflozin. Empagliflozin treatment decreased glucose and free fatty acid concentrations, while increasing beta-hydroxybutyrate levels.